Sigma-Aldrich this week launched its Panorama Human Cancer Version 1 Protein Functional Microarray.
Developed by Procognia and licensed exclusively through Sigma-Aldrich, the new protein microarray contains 130 folded proteins the firm claims are implicated in mediating cancer.
Kreatech Biotechnology last week launched its ULS labeling kits for protein science applications.
The Dutch company said the Serum ULS Protein Labeling and Fluorescent Detection Kit and the Cell Lysate ULS Protein Labeling and Fluorescent Detection Kit are intended for profiling of serum and cell lysate samples on high-content antibody arrays.
According to Kreatech, both have been validated on all currently available antibody array platforms.
Thermo Electron has released Galileo LIMS 3.1, which includes new functionality to support in vitro ADME/tox discovery laboratories. New features include automatic results flagging, rapid study entry, the addition of "IC50 shift" a new experiment type to elucidate enzyme inactivation, and support for PAMPA permeability studies. Galileo also includes interfaces for Thermo's more analytical instruments, including a bi-directional digital interface to Xcalibur v 1.4 and 2.0, the controlling software for the company's line of mass spectrometers.
Movers & Shakers
Jay Short has resigned as president and CEO of Diversa and has stepped down from the company's board, the San Diego-based company said last week. Edward Shonsey, Diversa's executive vice president of internal development, has been appointed as interim CEO.
Michael McGarrity has joined Nanosphere as chief marketing officer, the Northbrook, Ill.-based company said last week. He will help Nanosphere as it prepares to commercialize its Verigene platform for the detection of proteins and nucleic acids. McGarrity comes to Nanosphere from Stryker, where he was vice president of marketing for the Stryker Instruments division. He holds a degree from the University of Notre Dame.
Wylie Chenn has become regional director Asia/Pacific for Serologicals, the Atlanta, Ga.-based company said last week. He will work for the company's three business units, Celliance, Chemicon International, and the Upstate Group. Most recently, Chenn was general manager for the BioScience division, Asia Pacific, China Operations for Fisher Scientific. Chenn, who will be based in Hong Kong, holds an MBA in finance and economics from the University of Washington and a bachelor of science in marketing and international business from Brigham Young University.
Robert Young has been appointed to the board of directors of Human Genome Sciences, the company said this week. He is the president of the Fox Chase Cancer Center in Philadelphia. Young holds an MD from Cornell University Medical College and a BSc in zoology from Ohio State University.
Daniel Von Hoff has joined the oncology advisory board of Locus Pharmaceuticals, the Blue Bell, Pa.-based company said this week. He is the director of translational research at the Translational Genomics Research Institute in Arizona and a clinical professor of medicine at the University of Arizona.